Migraine patients with cranial autonomic symptoms (tearing, nasal congestion, eyelid swelling) had significantly greater headache reduction with anti-CGRP antibodies than those without these symptoms.
10 vs. 6 headache days reducedMigraine patients with cranial autonomic symptoms had nearly double the monthly headache reduction with anti-CGRP antibodies compared to those without (p=0.009)
What the researchers found
Out of 136 patients, 88 (65%) had cranial autonomic symptoms (CAS). During 12 weeks of anti-CGRP treatment, the median reduction in monthly headache days was significantly greater in patients with CAS (-10, IQR -15 to -6) versus without CAS (-6, IQR -12 to -3; p=0.009). However, categorical response rates (30%, 50%, 75%, 100% reduction thresholds) did not differ significantly between groups. The findings suggest CAS may serve as a clinical biomarker of trigeminovascular activation that predicts better response to CGRP-targeting therapies.
Why it matters
Predicting which migraine patients will respond best to expensive CGRP-targeting drugs is a major clinical challenge. This study identifies a simple, readily assessable clinical feature — cranial autonomic symptoms — that could help clinicians select the right patients for anti-CGRP treatment. Rather than trying the drug and waiting 12 weeks to assess response, doctors could potentially prioritize patients with CAS as likely strong responders.
How the study worked
Prospective real-world study of 136 patients with episodic or chronic migraine treated with anti-CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab) between 2019 and 2021. A 12-week baseline was compared to a 12-week treatment follow-up. CAS prevalence was assessed, and treatment responses were compared between CAS and non-CAS groups using appropriate statistical tests.
What this study cannot tell us
Relatively small sample size (136 patients) limits statistical power and generalizability. The categorical response rates didn't differ significantly between groups despite the median difference, suggesting the signal may be modest. The study combined three different anti-CGRP antibodies, and differential responses by drug type weren't analyzed. CAS assessment was clinical and may vary between providers. The 12-week follow-up is relatively short for a chronic condition.
How to read the evidence
This is a prospective real-world observational study with a moderate sample size. The finding is biologically plausible and statistically significant, but the observational design and relatively small numbers limit the strength of conclusions. Validation in larger cohorts is needed.
When this study was published
Published in 2022, this study reflects early real-world experience with anti-CGRP antibodies and contributes to the growing literature on treatment response predictors.
The bigger picture
The CGRP neuropeptide pathway has revolutionized migraine treatment, but not all patients respond equally well. Identifying clinical predictors of response is critical for cost-effective prescribing and patient satisfaction. CAS — which reflects activation of the trigeminovascular system (the main target of CGRP drugs) — makes biological sense as a predictor. This connects clinical phenotyping with molecular pathophysiology and could influence treatment guidelines.
Questions still open
- Could cranial autonomic symptoms be formally incorporated into treatment guidelines as a predictor of anti-CGRP response?
- Do specific types of CAS (e.g., tearing vs. nasal congestion) predict response better than others?
- Would patients with CAS also show better responses to CGRP-targeting gepants (small molecule antagonists)?
Common questions
What are cranial autonomic symptoms and why do they occur during migraine?
Should I tell my doctor about these symptoms when discussing migraine treatment?
Read the original research
Cranial autonomic symptoms and response to monoclonal antibodies targeting the Calcitonin gene-related peptide pathway: A real-world study.
Frontiers in neurology, 13, 973226
Citation
De Matteis, Eleonora; Caponnetto, Valeria; Casalena, Alfonsina; Frattale, Ilaria; Gabriele, Amleto; Affaitati, Giannapia; Giamberardino, Maria Adele; Maddestra, Maurizio; Viola, Stefano; Pistoia, Francesca; Sacco, Simona; Ornello, Raffaele. (2022). Cranial autonomic symptoms and response to monoclonal antibodies targeting the Calcitonin gene-related peptide pathway: A real-world study.. Frontiers in neurology, 13, 973226. https://doi.org/10.3389/fneur.2022.973226